ABOUT PSOMA COVID-19 RT CORONAVIRUS TEST
The Psoma COVID-19 RT Test from Psomagen is an in-vitro lab developed test (LDT) that uses real-time reverse transcription-polymerase chain reaction (RT-PCR) to detect RNA of the SARS-CoV-2 nucleocapsid gene (N1 and N2 target) and the RNaseP gene in upper respiratory and bronchoalveolar lavage specimens.
The method used increases the accuracy of the test results, effectively screening patients with trace amounts of COVID-19. The COVID-19 test from Psomagen is easy to administer and provides fast results. Laboratories certified under CLIA can conduct this PCR coronavirus test in-house. Laboratories in the U.S. and its territories are required to report all results to the appropriate public health authorities.
The FDA granted the Psoma COVID-19 RT Test Emergency Use Authorization on June 30, 2020. During Psomagen’s clinical trials for the tests, the company confirmed 100% consistency in 30 samples each in the positive and negative groups. The samples were collected from the upper and lower airways of COVID-19 patients.